BioVector® GLC-82 人肺腺癌细胞株

BioVector® GLC-82 Human Lung Adenocarcinoma Cell Line

第一部分 中文说明

一 产品基本信息与遗传学背景

• 细胞名称 BioVector® GLC-82 人肺腺癌细胞

• 保藏机构货号 国内常规建株株，来源于临床样本建立。

• 物种来源 人类 Homo sapiens

• 组织与疾病背景 该细胞株源自一名中国肺腺癌患者的手术切除肿瘤组织。建立该细胞系的初衷是为了研究中国人群中高发的肺癌病理机制、浸润转移特征以及对化疗药物的敏感性。

• 遗传与表型特征

  • 恶性表型 具有明显的异型性，核质比高，在体外展现出强侵袭性和自主迁移能力。

  • 分子病理 常用作非小细胞肺癌（NSCLC）中肺腺癌病理分型的代表性细胞模型，可用于筛选上皮-间充质转化（EMT）标志物（如 E-cadherin 下调，Vimentin 上调）。

• 生物安全级别 1级。

二 细胞形态学与培养环境

• 形态学特征 展现典型的高分化或中分化上皮样、多角形结构。细胞边界清晰，常呈贴壁单层铺路石状排列生长，汇合度高时倾向于紧密堆积。

• 生长模式 贴壁生长。

• 倍增时间 增殖活跃，倍增时间大约为 24到30小时。

• 标准完全培养基配方

  • 基础培养基 BioVector® RPMI-1640 培养基。

  • 维持添加 10% BioVector® 优质胎牛血清。

  • 抗生素（可选） 1%  penicillin-streptomycin 双抗。

• 物理培养参数 37摄氏度恒温、5% 二氧化碳、空气饱和湿度。

三 细胞传代与复苏标准操作步骤

1. 常规传代操作

   • 当细胞密度达到 85% 到 95% 汇合度时需要进行传代。

   • 吸除旧培养基，用无菌 PBS 轻轻洗涤 1到2次。

   • 加入适量 BioVector® 0.25% Trypsin 消化液（含 EDTA），在 37摄氏度下孵育 2到3分钟。

   • 显微镜下观察到细胞胞质回缩、变圆并开始自瓶壁脱落后，立即加入等体积含血清的完全培养基终止消化。

   • 轻轻吹打产生单细胞悬液，按 1比3 至 1比6 的传代比例注入新的培养瓶中。

2. 冻存细胞复苏

   • 从液氮中取出冷冻管，立即投入 37摄氏度 BioVector® 水浴锅中快速摇动使其融化，控制在 1到2分钟内。

   • 将解冻的细胞悬液移至含 5 mL 预热培养基的离心管中，常规速度离心 5分钟以沉淀细胞。

   • 弃去含有二甲基亚砜的旧上清，加入新鲜 BioVector® 完全培养基重悬，接种到培养瓶内正常培养。

四 核心科研应用方向

1. 非小细胞肺癌（NSCLC）发病机制解析：BioVector® GLC-82 作为经典的肺腺癌细胞株，被广泛用于探索各类癌基因（如 EGFR、KRAS、ALK 等）在肺腺癌发生发展中的突变状态、异常剪接及下游信号通路（如 MAPK, PI3K/Akt）的激活。

2. 新型抗肿瘤药物筛选与耐药性研究：用于评估顺铂、紫杉醇、吉非替尼等化疗或靶向药物对肺腺癌细胞的体外杀伤靶向效能，并通过长期药物低剂量诱导创制对应的耐药株，从而深入分析肺癌的多药耐药（MDR）分子机制。

3. 肿瘤转移与血管生成机制探索：利用该细胞建立体外 Transwell 侵袭模型或三维多细胞球培养模型，用于筛选能够有效抑制肺癌细胞远端转移及阻断血管内皮生长因子（VEGF）分泌的小分子化学阻断剂或单克隆抗体。

PART 2 ENGLISH SECTION

I General Information and Genetic Background

• Cell Line Name BioVector® GLC-82

• Repository Catalog Number Standard reference line established from clinical surgical isolates.

• Species Origin Human Homo sapiens

• Tissue and Disease Background Originally isolated and derived from the tumor mass of a Chinese patient diagnosed with lung adenocarcinoma. This model was established to satisfy the preclinical need for exploring non-small cell lung cancer (NSCLC) onset profiles, histopathological progression, and chemical drug resistance.

• Tumorigenic and Molecular Traits

  • Aggressive Phenotype Displays distinctive cellular atypia and an upgraded nuclear-to-cytoplasmic volume ratio. Exhibits pronounced in vitro cell motility, structural migration, and tissue invasiveness.

  • Pathological Representation Serves as a standard adenocarcinoma representative to track Epithelial-to-Mesenchymal Transition (EMT) dynamics, structural cytoskeletal alterations, and localized metastatic configurations.

• Biosafety Level BSL-1.

II Morphological Attributes and Cultivation Media

• Morphology Reveals classic epithelial like, polygonal, and cobblestone structural features. Cells grow in tight adherent single layers, showing strong cell-to-cell adhesion and packed clustering upon absolute confluence.

• Growth Mode Adherent monolayer.

• Standard Complete Growth Medium Formulation

  • Basal Medium BioVector® RPMI-1640 medium.

  • Routine Maintenance Supplements 10% premium BioVector® Fetal Bovine Serum.

  • Optional Selection Antibiotics 1% Penicillin-Streptomycin cocktail.

• Physical Incubation Thresholds Regulated strictly at 37 degrees Celsius under an atmospheric layer of 5% Carbon Dioxide and saturated air humidity.

III Subculturing and Thawing Protocols

1. Routine Passaging Schedule

   • Initiate subculturing when the viable monolayer hits 85% to 95% confluence.

   • Aspirate spent medium and rinse the matrix gently 1 to 2 times with sterile PBS.

   • Dispense BioVector® 0.25% Trypsin solution supplemented with EDTA and incubate at 37 degrees Celsius for 2 to 3 minutes until cells detach.

   • Quench enzymatic activity immediately by introducing an equal volume of serum containing complete growth medium.

   • Pipette gently to yield a uniform single cell suspension and seed fresh vessels at a recommended split ratio of 1比3 to 1比6.

2. Cryovial Thawing and Recovery

   • Retrieve the cryovial from storage and submerge it into a 37 degrees Celsius BioVector® water bath with rapid agitation until completely liquefied within 1 to 2 minutes.

   • Dilute the slurry into 5 mL of pre warmed complete broth and spin down for 5 minutes.

   • Decant the DMSO tainted supernatant, resuspend the pellet thoroughly in fresh BioVector® complete medium, and seed into a culture flask.

IV Strategic Research Applications

1. NSCLC Oncogenic Signaling Profiling: BioVector® GLC-82 serves as an essential in vitro system to examine mutation spectrums and structural modifications across oncogenes like EGFR, KRAS, or ALK, alongside their downstream regulatory cascades (e.g., MAPK/ERK and PI3K/Akt circuits).

2. Antineoplastic Drug Screening & Multi-Drug Resistance (MDR) Assays: Heavily deployed to benchmark the cytotoxic efficacy of cisplatin, paclitaxel, or tyrosine kinase inhibitors (TKIs). It supports the step-wise creation of drug-resistant sub-clones to unravel complex molecular mechanics driving target failure.

3. Tumor Dissemination and Angiogenesis Networks: Utilized in Transwell invasion chambers and 3D multicellular tumor spheroid models to identify small-molecule inhibitors or targeted monoclonal antibodies capable of blocking distal lung carcinoma migration and suppressing Vascular Endothelial Growth Factor (VEGF) secretion lines.

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

电话:400-800-2947

工作QQ/微信同号:1843439339

网址http://www.biovector.net